Ganymed Pharmaceuticals AG - Product Pipeline Review - 2015

  • ID: 3142676
  • Company Profile
  • 32 pages
  • Global Markets Direct
1 of 4
Ganymed Pharmaceuticals AG - Product Pipeline Review - 2015

Summary

This, ‘Ganymed Pharmaceuticals AG - Product Pipeline Review - 2015’, provides an overview of the Ganymed Pharmaceuticals AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ganymed Pharmaceuticals AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Ganymed Pharmaceuticals AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ganymed Pharmaceuticals AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Ganymed Pharmaceuticals AG’s pipeline products

Reasons to buy

- Evaluate Ganymed Pharmaceuticals AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ganymed Pharmaceuticals AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ganymed Pharmaceuticals AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ganymed Pharmaceuticals AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ganymed Pharmaceuticals AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Ganymed Pharmaceuticals AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Ganymed Pharmaceuticals AG Snapshot
Ganymed Pharmaceuticals AG Overview
Key Information
Key Facts
Ganymed Pharmaceuticals AG - Research and Development Overview
Key Therapeutic Areas
Ganymed Pharmaceuticals AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Ganymed Pharmaceuticals AG - Pipeline Products Glance
Ganymed Pharmaceuticals AG - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ganymed Pharmaceuticals AG - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Ganymed Pharmaceuticals AG - Drug Profiles
IMAB-362
Product Description
Mechanism of Action
R&D Progress
IMAB-027
Product Description
Mechanism of Action
R&D Progress
GT-352
Product Description
Mechanism of Action
R&D Progress
GT-353
Product Description
Mechanism of Action
R&D Progress
GT-468
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit CDLN18.2 for Solid Tumors
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit CLDN6 for Solid Tumor
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugates to Inhibit CDLN18.2 for Solid Tumors
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugates to Inhibit CLDN6 for Solid Tumors
Product Description
Mechanism of Action
R&D Progress
Ganymed Pharmaceuticals AG - Pipeline Analysis
Ganymed Pharmaceuticals AG - Pipeline Products by Target
Ganymed Pharmaceuticals AG - Pipeline Products by Route of Administration
Ganymed Pharmaceuticals AG - Pipeline Products by Molecule Type
Ganymed Pharmaceuticals AG - Pipeline Products by Mechanism of Action
Ganymed Pharmaceuticals AG - Recent Pipeline Updates
Ganymed Pharmaceuticals AG - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Ganymed Pharmaceuticals AG, Key Information
Ganymed Pharmaceuticals AG, Key Facts
Ganymed Pharmaceuticals AG - Pipeline by Indication, 2015
Ganymed Pharmaceuticals AG - Pipeline by Stage of Development, 2015
Ganymed Pharmaceuticals AG - Monotherapy Products in Pipeline, 2015
Ganymed Pharmaceuticals AG - Phase II, 2015
Ganymed Pharmaceuticals AG - Phase I, 2015
Ganymed Pharmaceuticals AG - Preclinical, 2015
Ganymed Pharmaceuticals AG - Discovery, 2015
Ganymed Pharmaceuticals AG - Pipeline by Target, 2015
Ganymed Pharmaceuticals AG - Pipeline by Route of Administration, 2015
Ganymed Pharmaceuticals AG - Pipeline by Molecule Type, 2015
Ganymed Pharmaceuticals AG - Pipeline Products by Mechanism of Action, 2015
Ganymed Pharmaceuticals AG - Recent Pipeline Updates, 2015

List of Figures
Ganymed Pharmaceuticals AG - Pipeline by Top 10 Indication, 2015
Ganymed Pharmaceuticals AG - Pipeline by Stage of Development, 2015
Ganymed Pharmaceuticals AG - Monotherapy Products in Pipeline, 2015
Ganymed Pharmaceuticals AG - Pipeline by Top 10 Target, 2015
Ganymed Pharmaceuticals AG - Pipeline by Top 10 Route of Administration, 2015
Ganymed Pharmaceuticals AG - Pipeline by Top 10 Molecule Type, 2015
Ganymed Pharmaceuticals AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll